Results 1 to 10 of about 12,436 (107)

Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study. [PDF]

J Cachexia Sarcopenia Muscle
ABSTRACT Background Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder that affects dystrophin production, characterized by progressive neuromuscular dysfunction, often accompanied by osteoporosis. We prospectively evaluate the effects of bisphosphonates on bone micro‐architecture reflected by trabecular bone score (TBS) of patients ...
Wang S, Dai Y, Meng L, Zhang Y, Sun L, Wang Y, Wang O, Jiang Y, Xia W, Xing X, Yu W, Li M.   +11 more
europepmc   +2 more sources

Nickel alendronate [PDF]

Acta Crystallographica Section E Structure Reports Online, 2012
The title compound {systematic name: bis(μ2-dihydrogen 4-azaniumyl-1-hydroxybutane-1,1-diphosphonato)bis[aqua(dihydrogen 4-azaniumyl-1-hydroxybutane-1,1-diphosphonato)nickel(II)] dihydrate}, [Ni2(C4H12NO7P2)4(H2O)2]·2H2O, was synthesiized under hydrothermal conditions. Its structure is isotypic with the CoII analogue.
Małgorzata Sikorska, Maria Gazda, Jaroslaw Chojnacki   +2 more
openaire   +3 more sources

Alendronate gastric ulcers [PDF]

Alimentary Pharmacology & Therapeutics, 1999
Background: It appears likely that drugs other than NSAIDs may cause ulcers and ulcer complications (e.g. potassium chloride). Alendronate (Fosamax) is used in the treatment and prevention of metabolic bone disease and has also been associated with severe oesophageal damage and stricture.
D Y, Graham, H M, Malaty
openaire   +2 more sources

Seizures after alendronate

JRSM, 2002
Alendronate and other bisphosphonates are effective in the prevention and treatment of osteoporosis by inhibiting bone resorption. In normal circumstances a small initial fall in serum calcium has no clinical consequences because it is corrected by an increase in parathyroid hormone (PTH) secretion1.
Richard J, Maclsaac, Ego, Seeman, George, Jerums   +2 more
openaire   +3 more sources

Bond strength and interfacial stability of a universal adhesive to alendronate-treated dentin. [PDF]

Sci Rep
Salem HS, Enan ET, Hamama H, Ismail MS.
europepmc   +1 more source

In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation. [PDF]

NPJ Syst Biol Appl
Kim YK, Kameo Y, Tanaka S, Adachi T.
europepmc   +1 more source

Use of bmps as a treatment for medication-related maxillary osteonecrosis (mronj): a systematic review. [PDF]

Acta Odontol Scand
Hernando-Calzado L, Bauer-González A, Cobo-Vázquez CM, Meniz-García C, López-Quiles J, Madrigal Martínez-Pereda C.   +5 more
europepmc   +1 more source

Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis. [PDF]

Bone Rep
Anastasilakis AD, Makras P, Polyzos SA, Yavropoulou MP, Papapoulos SE.   +4 more
europepmc   +1 more source

Comparative Molecular Docking, Molecular Dynamics and Adsorption-Release Analysis of Calcium Fructoborate and Alendronate Salts on Hydroxyapatite and Hydroxyapatite-Titanium Implants. [PDF]

Biomedicines
Trasca DM, Pluta ID, Sirbulet C, Varut RM, Singer CE, Preoteasa D, Stoica GA.   +6 more
europepmc   +1 more source

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Chen L, Wang Q, Gu M.
europepmc   +1 more source